openPR Logo
Press release

Market Overview of Cardiovascular Disease Industry 2018

01-03-2018 11:39 AM CET | Health & Medicine

Press release from: Cardiovascular Disease

Albany, NY, 3rd January : Recent research and the current scenario as well as future market potential of "Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis" globally.

The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1313843

The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque building up within blood vessels. As atheroma develops it causes the affected blood vessels to narrow, restricting blood flow to the body, brain or heart, depending on its location. It is also possible for the fibrous cap of this plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally, which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: anti-hypertensives, which aim to alterblood pressure to within a normal range; anti-dyslipidemic drugs, which aim to modify lipid levels to a normal range; and anti-thrombotic drugs, which aim to either prevent a thrombus from formingby inhibiting the coagulation cascade or platelet aggregation.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market, first with the introduction of statins such as Lipitor (atorvastatin), and more recently with the introduction of PCSK9 inhibitors. Innovation continues within the dyslipidemia pipeline, with a range of first-in-class molecular targets in the pipeline, including those that offer the promise of revolutionizing treatment by reversing the process of atherosclerosis.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/frontier-pharma-cardiovascular-disease-diverse-first-in-class-molecular-targets-to-bridge-unmet-needs-in-pulmonary-hypertension-heart-failure-and-atherosclerosis-report.html/toc

Heart failure and pulmonary hypertension remain poorly treated, and are associated with poor prognosis. Heart failure in particular is associated with a five-year mortality rate of 50%. The large pipeline for heart failure includes a high proportion of first-in-class products relative to other CVD indications, and possesses the potential for breakthroughs in the treatment of this condition.

Scope

- With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?
- There are 320 first-in-class products in the CVD market that act on a novel molecular target thatis not present in an approved product across any indication in the pharmaceutical industry. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
- Analysis of the history of strategic consolidations revealed a modest level of deal activity in recent years, and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs that have not yet been involved in a licensing or co-development deal appear to be particularly promising?

Reasons to buy

- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
- Visualize the composition of the CVD market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the CVD pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating CVD to overcome the unmet need in the market.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.

Browse Report @ https://www.researchmoz.us/frontier-pharma-cardiovascular-disease-diverse-first-in-class-molecular-targets-to-bridge-unmet-needs-in-pulmonary-hypertension-heart-failure-and-atherosclerosis-report.html

- Identify commercial opportunities in the CVD deals landscape by analyzing trends in licensing and co-development deals, and analyzing a curated list of CVD therapies that have not yet been involved in deals, and may offer potential investment opportunities.

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Market Overview of Cardiovascular Disease Industry 2018 here

News-ID: 883149 • Views: 142

More Releases from Cardiovascular Disease

Deep Research: Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class …
Researchmoz added Most up-to-date research on "Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis" to its huge collection of research reports. An insight on the important factors and trends influencing the market. The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD
Clinical Trials On Cardiovascular Disease: Frontier Pharma
Researchmoz added Most up-to-date research on "Clinical Trials On Cardiovascular Disease: Frontier Pharma" to its huge collection of research reports. The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque building up within blood vessels. As atheroma develops it causes the affected blood
Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unme …
Researchmoz added Most up-to-date research on "Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis" to its huge collection of research reports. The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque building up
Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targe …
ResearchMoz added Latest Research Report titled " Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis " to it's Large Report database. Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis Summary The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood

All 5 Releases


More Releases for CVD

CVD SiC Market Size Estimation by Experts 2019
The global CVD SiC market is valued at 130 million US$ in 2018 is expected to reach 240 million US$ by the end of 2025, growing at a CAGR of 7.3% during 2019-2025. CVD SiC is a kind of SiC materials produced via Chemical Vapor Deposition(CVD) process. CVD SiC material has a unique combination of excellent thermal, electrical and chemical properties that makes it well-suited to applications across semi-conductor industries where a
Global CVD SiC Market Opportunities, Trends and Forecast to 2025
Qyresearchreports include new market research report "Global CVD SiC Market Research Report 2018" to its huge collection of research reports. The global CVD SiC market has been deeply assessed in this report compiled by experienced researchers and analysts of the industry. The authors have made it a point to make it simpler for readers to understand the important trends of the market and how players could gain a strong growth in
Angiography Devices Market: Strong Prevalence of CVD Driving Demand
A fresh business intelligence publication by Transparency Market Research (TMR) informs that the global angiography devices market is highly competitive, attributing it to the presence of a vast pool of players who operate at regional as well as international level. The major manufacturers of angiography devices are aspiring greater shares by aggressively pricing their products, developing new technologies that meets diverse demands, and strengthening their distribution network. Medtronic Inc., AngioDynamics,
CVD Coating Technology Market : Analysis and Forecast by 2024
CVD (Chemical Vapor Deposition) is an atmosphere controlled coating process carried out at high temperatures and is usually carried out in CVD reactors. It is mainly employed for surface coating process to produce high purity bulk materials that are used across various industries. Ongoing technological advancements and innovations in the CVD (Chemical Vapor Deposition) technology are anticipated to supplement the growth of global CVD Coating Technology Market over the forecast
Global Semiconductor CVD Equipment Market: Industry Size, Share, Growth, Forecas …
Latest industry research report on: Global Semiconductor CVD Equipment Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Semiconductor CVD Equipment Report by Material, Application, and Geography Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South
CVD Coating Technology Market - Opportunities and Forecast Assessment, 2017 – …
CVD (Chemical Vapor Deposition) is an atmosphere controlled coating process carried out at high temperatures and is usually carried out in CVD reactors. It is mainly employed for surface coating process to produce high purity bulk materials that are used across various industries. Ongoing technological advancements and innovations in the CVD (Chemical Vapor Deposition) technology are anticipated to supplement the growth of global CVD Coating Technology Market over the forecast